Dr. Finn believes that it is reasonable to continue with another chemoembolization procedure at this time, but the real question for the practicing clinician is, when does the patient go beyond a chemoembolization procedure? There would be several reasons for doing so; for example, if the patient has evidence of decompensation from his treatment or his disease, such as hyperbilirubinemia or ascites. He could develop vascular invasion, which could be a contraindication for chemoembolization and systemic treatment would then be appropriate, or he could develop extrahepatic disease, which would be an indication for systemic therapy as well, as would pure progression after chemoembolization, even intrahepatic progression, with other satellite lesions or growth at the main lesion.
CASE 1: Unresectable Hepatocellular Carcinoma
Jose V is a 73-year-old Filipino store owner from Queens, New York, with a history of chronic hepatitis B (HBV) infection and unresectable hepatocellular carcinoma (uHCC).
In May 2014, patient was referred to a hepatologist with an elevated ALT (68 IU/mL)
Medical history includes type II diabetes, previously treated with metformin and a sulfonylurea; currently controlled with diet and exercise regimen; other MH was unremarkable
Family history was relevant for a sister who was diagnosed with HCC and chronic HBV infection at age 60
No symptoms of liver disease were noted; patient had mild tenderness over the right upper quadrant
Ultrasound revealed a hyperechoic lesion in the left lobe; MRI with gadolinium showed an 11-cm mass in the left lobe with imaging characteristics consistent with HCC. No evidence of metastatic disease was noted on bone scan and uncontrasted CT scan of the chest.
Based on laboratory findings and clinical features, the patient was determined to have Child Pugh Class A, with a MELD score of 8
Consultation with the multidisciplinary team recommended surgical resection, however patient was fearful of surgery and opted for TACE procedure
In June of 2014, follow-up CT scan showed evidence of residual disease at the TACE site; a second TACE was scheduled for 10 weeks following the first TACE. In August of 2014, an MRI showed evidence of residual disease in the periphery of the tumor approximately 6 weeks following the second TACE procedure.
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More